Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)
1.1299 -0.1201 (-9.61%) 11:50 ET [NASDAQ]
1.1200 x 6,900 1.1300 x 7,200
Realtime by (Cboe BZX)
1.1200 x 6,900 1.1300 x 7,200
Realtime 1.2400 -0.0100 (-0.80%) 09:16 ET
News & Headlines for Thu, Apr 3rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
CNS Pharmaceuticals (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, down from $18.9 million in 2023, due to reduced R&D...

CNSP : 1.1299 (-9.61%)
CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Company has one year of cash to fund operations

CNSP : 1.1299 (-9.61%)
CNS Pharmaceuticals (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma Trial

CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM). While the study did not meet its primary...

CNSP : 1.1299 (-9.61%)
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.

CNSP : 1.1299 (-9.61%)
CNS Pharmaceuticals (NASDAQ: CNSP) Updates Cash Position, Nasdaq Compliance, and Clinical Progress

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company focused on treatments for brain and central nervous system cancers, provided an update on its cash position and efforts to maintain its Nasdaq...

CNSP : 1.1299 (-9.61%)
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

Cash on hand provides over one year of runway to fund expected operations

CNSP : 1.1299 (-9.61%)
CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum

CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present at the 18th Annual European Life Sciences CEO Forum in Zurich on Feb. 26, 2025, at 3:20 p.m. CET / 9:20 a.m. EST; management...

CNSP : 1.1299 (-9.61%)
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the Virtual Investor Top 5 for ‘25 On-Demand Conference, where CEO John Climaco outlined five key reasons for investors and industry...

CNSP : 1.1299 (-9.61%)
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

Webcast presentation Wednesday, February 26th at 3:20 PM CET

CNSP : 1.1299 (-9.61%)
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the 6th Glioblastoma Drug Development Summit, taking place Feb. 18-20, 2025, in Boston. Chief Medical Officer Dr. Sandra Silberman will...

CNSP : 1.1299 (-9.61%)

Barchart Exclusives

Dear Nvidia Stock Fans, Mark Your Calendars for May 15
The stock may experience volatlility until this catalyst passes. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades